List Of Malaria Pharmaceutical Products
classified according to the Global Fund Quality Assurance Policy

Edition: Version 107 - 03rd July 2020

The list is an overview of pharmaceutical products subject to the Global Fund Quality Assurance Policy that are listed in National and/or WHO standard treatment guidelines and classified according to the various options (A, B, and ERP reviewed) defined in the Global Fund Quality Assurance Policy (July 2009, amended in December 2010). The list is developed as a tool to assist Principal Recipients (PR) of Global Fund grants to identify the status of finished pharmaceutical products according to the Global Fund Quality Assurance Policy.

The pharmaceutical products are classified based on the following information

A classified product - Listed on WHO prequalification list;
B classified product - Stringent NDRA Registration letter/Marketing Authorization;
ERP reviewed product- **Permitted for time-limited procurement** based on advice by the Expert Review Panel (ERP);

Please note that the list is not an exhaustive list. A PR can procure product(s) not listed in the current list as long as PR demonstrates that the product is compliant with the Global Fund Quality Assurance Policy.

The Global Fund list includes the following information:

- "Important Notes" for helpful information;
- A, B, and ERP reviewed products;
- Period validity of the ERP reviewed products;
- "+" means combination product, both fixed-dose combination (co-formulated) and co-packaged product (i.e. co-blister)
- [A+B]+C means A and B are in fixed-dose formulation and C is co-packaged
YELLOW signifies a new entry; PINK signifies modification of an existing entry.

For more information, please look at:
https://www.theglobalfund.org/en/sourcing-management/quality-assurance/.

Expert Review Panel (ERP): Expert Review Panel is an independent technical body composed of external technical experts, hosted by WHO Department of Essential Medicines and Pharmaceutical Policies, to review the potential risks/benefits associated with the use of FPPs that are not yet WHO-prequalified or SRA-authorized and to advise the Global Fund in its decision on whether to allow grant funds to be used to procure FPP. ERP reviewed products can be procured for a limited time (maximum 12 months). However, under certain circumstances, it is possible to extend the recommendation period. Contracts to supplier/manufacturer for an ERP reviewed products should not be longer than the validity period of the recommendation of that product. For detail information on ERP process and Quality Assurance information, please look at https://www.theglobalfund.org/en/sourcing-management/quality-assurance/.

Procurement of ERP Reviewed Products: Principal Recipients (PRs) must inform the concerned Fund Portfolio Manager (FPM) at the Global Fund in writing by filling the "Notification Form" (available on website) if they intend to procure
ERP-reviewed product(s). The Global Fund Secretariat will review the notification request and upon issuing a " no objection" letter to the PR for the requested selection, procurement can only proceed.

Important Notes

This List may be used by Principal Recipients of Global Fund grants when considering options with respect to procurement of pharmaceutical products pharmaceutical products subject to the Global Fund Quality Assurance Policy. The list aims at providing countries with information that will assist them in their procurement options. Please note that the list is not designed to be a basis for countries to select medicines to be included in their National Treatment Guidelines or to replace any applicable and legally required procurement processes. The Global Fund requires its grant recipients to comply with applicable procurement laws and provides the list only for the **identification of products/manufacturers that comply with the Global Fund's quality assurance policy**. It is important to note that there is no strict requirement to procure according to the list, as long as the Principal Recipients can ensure that the product selected is compliant with the Quality Assurance policy criteria. Furthermore, the Principal Recipient should not rely solely on the information provided in the list but should obtain evidence of products compliance with the Quality Assurance policy. For the above reasons, **we strongly encourage users to ensure they are using the most recent version on our website when conducting procurement.**

The Lists will be updated regularly based on evidence received by the Global Fund. Interested parties are invited to supply information and evidence of products meeting the policy criteria on an ongoing basis. For the above reasons, **we strongly encourage users to ensure they are using the most recent version on our website when conducting procurement.**

According to the Global Fund QA policy, if there are two or more A or B classified manufacturers available for any given product AND the product is available from these manufacturers (available-means that the manufacturer can supply the selected product within 90 days after receiving the Purchase Order), then such product must be procured from A or B classified product manufacturers. The PR must notify by writing to the Global Fund Secretariat (Fund Portfolio Manager) and recieve the "No Objection" letter from GF secretariat before procuring any products complying with option " ERP Reviewed".

For ease of reference, each "product" has been identified in this list with a unique "Product reference number" (Column A). Please see examples below.

Several different dosage forms may be grouped under the same Product Reference Number and therefore will be considered the same type of products when identifying the number of available manufacturers for the application of this policy. These products share the same dosing protocol, target the same population, and there are no fundamental differences among them. For example, within solid forms, some capsules will have same reference number as tablets while within liquids, oral solution and suspension are grouped together.Similarly, the entero coated tablet or dispersible tablet will not share the same reference number as non entero coated or dispersible tablets.

Product Ref. No	International Non-proprietary name	Strength	Dosage form	Supplier/Manufacturer *	Global Fund QA Standard	WHO Pre-qualified/ SRA	Manufacturing site*	Country	Material	Pack
16	**XYZ**	**50mg**	Tablet	"Pharma Company A"	A - B	Yes	"Pharmaville"	Country A	HDPE bottle	60
17		**100mg**	Tablet	"Pharma Company B"	A - B	Yes	"Pharmaville"	Country B	HDPE bottle	60

The example above shows 2 different variants of the same medicine. Because the strength is different, it is considered 2 different products (there are two different reference numbers 16 and 17). If the strength had been the same but the dosage form had been different (i.e. tablet and liquid) it would also have been considered two different "products".

Product Ref. No	International Non-proprietary name	Strength	Dosage form	Supplier/Manufacturer*	Global Fund QA Standard	WHO Pre-qualified/ SRA	Manufacturing site*	Country	Packaging	
									Material	Pack
25	**ABC**	**150mg**	Tablet	"Pharma Company A"	A - B	Yes	"Pharmaville"	Country A	Blister, HDPE bottle	10, 60
			Capsules	"Pharma Company B"	A - B	Yes	"Pharmaville"	Country B	HDPE Bottle, Blister	60, 10

In this second example both products have same reference number (25) because both manufacturers are supplying the same strength and the dosage forms are considered similar as per explanation above.

*** See below**

Disclaimer:

The Global Fund does not endorse or warrant the fitness of any product on the List for a particular purpose, including in regard of its safety and/or efficacy in the treatment of HIV/AIDS, tuberculosis or malaria. In addition, the Global Fund assumes no responsibility for any misstatement or omission from the list and directs Principal Recipients of Global Fund grants to conduct their own independent confirmation that the information on a given product on the list is accurate before relying on it to make a purchase order for that product, and to ensure that any purchase is in compliance with all the requirements of the Global Fund's quality assurance policy. The Global Fund does not warrant or represent that the products listed have obtained regulatory approval for use of treatment of any disease in any particular country of the world, or that their use is otherwise in accordance with the national laws and regulations of any country, including, but not limited to, intellectual property laws. The Global Fund disclaims any and all liability and responsibility for any injury, death, damage or loss of any kind whatsoever that may arise as a result of, or in connection with the procurement, distribution and use of any product included in the list.

*** As from the version 89, please note that we consider under**

Supplier / Manufacturer :
Marketing authorization/ product authorization or license holder

Manufacturing Site:
The Site responsible for the release of the FPP.

List of A or B products:

If there are two or more 'A' or ' B" products available, then the product must be procured from one of the A or B products.
Note: if the product intended for selection is not listed in this list , please refer to the List of ERP (Expert Review Panel) Reviewed Products which are permitted for time limited procurement:

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
1	Artesunate	30 mg	Powder for injection	Guilin Pharmaceutical Co. Ltd	A	Yes	Guilin, Guangxi,	China	Glass Vial	Vial; 1 vial of artesunate powder is co-packed with 1 ampoule of sodium bicarbonate injection (0.5mL:25mg) and 1 ampoule of sodium chloride injection (2.5mL:22.5mg)
2	Artesunate	60 mg	Powder for injection	Guilin Pharmaceutical Co. Ltd	A	Yes	Guilin, Guangxi,	China	Glass Vial	Vial [1 vial of artesunate powder is co-packed with 1 ampoule of sodium bicarbonate injection (1ml:50mg) and 1 ampoule of sodium chloride injection (5ml:45mg)]

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
	Artesunate	60 mg	Powder for injection	Ipca Laboratories Ltd	A	MA135	Ipca Laboratories Ltd, Sejavta, Ratlam, Madhya Pradesh, 457 002	India	Glass Vial	Powder, solvent and diluent for solution for injection 60mg + 5%w/v + 0.9%w/v- 1ml of sodium bicarbonate 5% w/v, ampoule: 5ml of sodium chloride 0.9% w/v
3	Artesunate	120 mg	Powder for injection	Guilin Pharmaceutical Co. Ltd	A	Yes	Guilin, Guangxi,	China	Glass Vial	Vial; 1 vial of artesunate powder is co-packed with 1 ampoule of sodium bicarbonate injection (2mL:100mg) and 1 ampoule of sodium chloride injection (10mL:90mg)
	Arthemether	80mg/ml	Solution for injection	Sanofi	A	MA087	Haupt Pharma Livron SAS, 1 rue Comte de Sinard, Livron sur Drôme, 26250	France	Glass Vial	Ampoule, 1mlx6
4	Artemether + Lumefantrine (FDC)	20 mg+120 mg	Tablet	Novartis Pharma	A - B	Yes	Beijing; Suffern Philadelphia Istambul	China USA Turkey	Blister	6, 12, 18, 24
	Artemether + Lumefantrine (FDC)	20 mg+120 mg	Tablet	Ajanta Pharma	A	Yes	Paithan, Aurangabad	India	PVC/PVdC/Alu blister	2*8, 3*8, 6*30, 12*30, 18*30, 24*30
	Artemether + Lumefantrine (FDC)	20 mg+120 mg	Tablet	Cipla Ltd.	A	MA064	Patalganga; Himachal Pradesh, Goa Kurkumbh, Indore; Quality Chemical Industries Ltd, Kampala,	India Uganda	PVC-PCTFEE/ Alu Blister Alu-Alu Blister	6, 12, 18, 24
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Tablet	IPCA Laboratories Ltd	A	Yes	Dadra and Nagar Haveli,	India	Alu/PVC/ PVDC Blister	6, 12, 18, 24

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Tablet	Strides Arcolab Limited	A	Yes	Bangalore	India	PVC/PE/ PVDC/Alu blister	4 x 6's
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Tablet	Macleods	A	Yes	Kachigam Daman Oxalis lab, Baddi Solan Dist	India	Al/PVC/PE/PVDC Al/PVC/Aclar blister	blister 3 x 8; 1 x 6, 2 x 6, 3 x 6, 4 x 6
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Tablet	Mylan Labs	A	Yes	Sinnar, Nashik, Maharashtra,	India	Alu/Alu blister	1x6, 2x6, 3x6 & 4x6
5	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Dispersible tablets	Novartis Pharma	A	Yes	Rockford, Illinois Conshohocken, Pennsylvania Suffern Istambul Beijing	USA Turkey China	PVC/Alu blister or PVC/PCTFE/Alu blister	6*30; 12*30; 18*30
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Dispersible tablets	Ajanta Pharma	A	Yes	Paithan, Aurangabad, Maharashtra	India	PVC/PVdC/Alu blister	6, 12
	Artemether + Lumefantrine (FDC)	20 mg + 120 mg	Dispersible tablets	Strides Shasun Limited	A	MA110	Oral Solid Dosage Forms Division, KRS Gardens, 36/7, Suragajakkanahalli, Indlawadi Cross, Anekal Taluk, Bangalore, Karnataka, 562 106	India	Alu/PVC/ PVdC	6x1, 12x1
	Artemether + Lumefantrine	20mg+120mg	Dispersible Tablet	IPCA Laboratories Ltd	A	MA136	Ipca Laboratories Ltd - Plot No : 255/1, Village Athal, Dadra and Nagar Haveli (U.T), Silvassa – 396 230, India	India	Alu-Alu blister and PVC/ACLAR/PVC-Alu blister	1 × 6's 1 × 12's 30 × 1 × 6's 30 × 1 × 12's 30 × 6's 30 × 12's
	Artemether + Lumefantrine	20mg+120mg	Dispersible Tablet	Cipla Limited	A	MA115	Cipla Ltd, Unit IV, Plot No 9, 10 & 15 Indore Special Economic Zone, Phase II, Pithampur, Dhar District, Madhya Pradesh, 454 775, India	India	Alu/PVC/ Aclar/PVC blister	6x1;12x1;18x1;6x30 ;12x30;18x30

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
	Artemether + Lumefantrine	20mg+120mg	Dispersible Tablet	Macleods Pharmaceuticals Ltd	A	MA137	Oxalis Labs, Vill. Theda, P.O.lodhimajra, Baddi, Distt. Solan	India	Bilster, Alu-PVC/PE/ PVdC	6x17
6	Artemether + Lumefantrine (FDC)	40 mg + 240 mg	Tablet	Mylan Labs	A	Yes	Sinnar, Nashik, Maharashtra,	India	Alu/Alu blister	1x12
	Artemether + Lumefantrine (FDC)	40 mg + 240 mg	Tablet	Ajanta Pharma	A	MA128	B4/5/6 MIDC Industrial Area, Aurangabad, Paithan District, Maharashtra	India	Alu/PVC-PVdC, Blister	6x1
	Artemether + Lumefantrine	40mg+240mg	Tablet	Cipla Limited	A	MA120	Vill. Malpur, Baddi, Distt. Solan (H.P.) 173205	India	Alu/PVC/ Aclar/PVC blister	6x1
	Artemether + Lumefantrine	40mg +240mg	Tablet FDC	Macleods Pharmaceuticals Ltd	A	MA143	Oxalis Labs Village Theda, P.O Lodhimajra, Baddi, Distt. Solan, Himachal Pradesh, 174101	India	Alu/PVC/PE/ PVDC Blister	10x10
	Artemether + Lumefantrine (FDC)	60 mg + 360 mg	Tablet	Ajanta Pharma	A	MA129	B4/5/6 MIDC Industrial Area, Aurangabad, Paithan District, Maharashtra	India	Alu/PVC-PVdC, Blister	6x1
	Artemether + Lumefantrine	60mg+360mg	Tablet	Cipla Limited	A	MA121	Vill. Malpur, Baddi, Distt. Solan (H.P.) 173205	India	Alu/PVC/ Aclar/PVC blister	6x1
7	Artemether + Lumefantrine (FDC)	80 mg + 480 mg	Tablet	Ajanta Pharma	A	MA130	B4/5/6 MIDC Industrial Area, Aurangabad, Paithan District, Maharashtra	India	Alu/PVC-PVdC, Blister	6x1
	Artemether + Lumefantrine (FDC)	80 mg + 480 mg	Tablet	Novartis Pharma	A	Yes	Ramapo, Rockland County Philadelphia, Pennsylvania Rockford, Illinois Istambul	USA; Turkey	PVC/PE/ PVDC/Alu blister	1x6
	Artemether + Lumefantrine	80mg+480mg	Tablet	Cipla Limited	A	MA122	Vill. Malpur, Baddi, Distt. Solan (H.P.) 173205	India	Alu/PVC/ Aclar/PVC blister	6x1

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
	Artemether + Lumefantrine	80mg+480mg	Tablet, film coated	Macleods Pharmaceuticals Ltd	A	MA142	Oxalis Labs, Vill. Theda, P.O.lodhimajra, Baddi, Distt. Solan	India	Blister Alu/PVC/ PE/PVdC	15x10
	Artemether + Lumefantrine	80mg+480mg	Tablet FDC	Strides Pharma Global PTE Limited	A	MA138	Strides Pharma Science Limited, Oral Solid Dosage Forms Division, KRS Gardens, 36/7, Suragajakkanahalli, Indlawadi Cross, Anekal Taluk, Bangalore, Karnataka, 562 106	India	PVC/PE/PV DC blister	6x1
	Artesunate	100mg	Suppository	Cipla Limited	A	MA124	Cipla Limited, D7, MIDC Industrial area Kurkumbh Dist Pune 413802 INDIA	India	Alu/Alu Blister	2'
	Artesunate	100 mg	Suppository	Strides Shasun Ltd - India	A	MA123	Strides Shasun ltd-36/7, Suragajakkanahalli Indlavadi Cross, Anekal Taluk Bangalore	India	Alu/Alu (Alu foil/OPA/ Alu/PVC) blister	2'
8	Artesunate + Amodiaquine (Co-Blistered)	50 mg + 150 mg	Tablet	Guilin Pharmaceutical Co. Ltd	A	Yes	Guilin, Guangxi,	China	PVC/ALU blisters;	3x(4+4), 3+3, 6+6, 12+12
9	Artesunate + Amodiaquine (Co-Blistred)	50 mg + 153 mg (200mg as Hydrocloride)	Tablet	Cipla Ltd.	A	Yes	Goa; Patalanga	India	PVC/PVD C/Alu blister	3+3, 6+6, 12+12
	Artesunate + Amodiaquine (Co-Blistered)	50 mg + 153 mg (200mg as Hydrocloride)	Tablet	IPCA Laboratories Ltd	A	Yes	Dadra and Nagar Haveli	India	PVdC/PV C/Alu blister	12+12, 6+6, 3+3
	Artesunate + Amodiaquine (Co-Blistered)	50 mg + 153 mg	Tablet	Strides Arcolab Limited	A	Yes	Bangalore	India	PVdC/PV C/Alu blister	10x(12+12), 10x (6+6), 10x(3+3)
10	Artesunate + Pyronaridine	60mg+180mg	Tablet	Shin Poong Pharmaceutical Co., Ltd, S.Korea	A-B	EMA Art 58 H-W-2319	Shin Poong Pharmaceutical Co., Ltd,Gyeonggi-do	S.Korea	Aluminium/PVC/Aluminium-oPA foil blisters	90(9'sx10)

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
11	Artesunate + Pyronaridine	20mg+60mg	granules	Shin Poong Pharmaceutical Co., Ltd, S.Korea	A-B	EMA Art 58 H-W-2319-3	Shin Poong Pharmaceutical Co., Ltd,Gyeonggi-do	S.Korea	Sachet	90
12	Amodiaquine+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Sanofi Aventis	A	Yes	Maphar Lab,Casablanca	Morocco	Al/Alu Blister	3*1, 3*25
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	IPCA Laboratories Ltd	A	Yes	Dadra and Nagar Haveli	India	Al/Alu Blister	10x1x3; 25x3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Guilin Pharmaceutical Co. Ltd	MA083	Yes	Guilin, Guangxi, China	China	Alu/PA/Alu/PVC blister	3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Ajanta Pharma	A	Yes	Paithan, Aurangabad, Maharashtra	India	Al/Alu Blister	1x3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Cipla Ltd.	A	Yes	Patalganga	India	Blister	1X3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Micro Labs Ltd	A	MA132	Plot No. S-155 to S-159 & N1, Phase III & Phase IV, Verna Industrial Estate, Verna, Goa, 403 722	India	Blister,Alu/Alu; Blister, Alu-PVC/Aclar	3x1, 3x10, 3x25
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	67.5 mg + 25 mg	Tablet	Macleods Pharmaceuticals Ltd	A	MA125	Unit 2, Plot No 25-27, Survey No 366, Premier Industrial Estate, Kachigam, Daman, 396 210	India	Blister;Alu/Alu	10x10
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	Micro Labs Ltd	A	MA133	Plot No. S-155 to S-159 & N1, Phase III & Phase IV, Verna Industrial Estate, Verna, Goa, 403 722	India	Blister,Alu/Alu; Blister, Alu-PVC/Aclar	3x1, 3x10, 3x25
13	Amodiaquine+Artesunate (FDC)	135 mg + 50 mg	Tablet	Sanofi Aventis	A	Yes	Maphar Lab,Casablanca	Morocco	Al/Alu Blister	3*1, 3*25
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	IPCA Laboratories Ltd	A	Yes	Dadra and Nagar Haveli,	India	Al/Alu Blister	10x1x3; 25x3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	Guilin Pharmaceutical Co. Ltd	MA084	Yes	Guilin, Guangxi, China	China	Alu/PA/Alu/PVC blister	3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	Ajanta Pharma	A	Yes	Paithan, Aurangabad, Maharashtra	India	Al/Alu Blister	1x3

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	Cipla Ltd.	A	Yes	Patalganga	India	Blister	1X3
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	135 mg + 50 mg	Tablet	Macleods Pharmaceuticals Ltd	A	MA126	Unit 2, Plot No 25-27, Survey No 366, Premier Industrial Estate, Kachigam, Daman, 396 210	India	Blister;Alu/Alu	10x10
14	Amodiaquine+Artesunate (FDC)	270 mg +100 mg	Tablet	Sanofi Aventis	A	Yes	Maphar Lab,Casablanca, Morocco; Rottendorf Pharma, Ennigerloh, Germany; Batch released by: I41Sanofi-Aventis Maroc, Casablanca, Morocco	Morocco Germany	Al/Alu Blister	3*1, 3*25,6*1, 6*25
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	IPCA Laboratories Ltd	A	Yes	Dadra and Nagar Haveli,	India	Al/Alu Blister	10x1x3; 10x1x6; 25x3; 25x6
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	Guilin Pharmaceutical Co. Ltd	MA085	Yes	Guilin, Guangxi, China	China	Alu/PA/Alu/PVC blister	3, 6
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	Ajanta Pharma	A	Yes	Paithan, Aurangabad, Maharashtra	India	Al/Alu Blister	1x3, 1x6
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	Cipla Ltd.	A	Yes	Patalganga	India	Blister	1X3, 1X6
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	Micro Labs Ltd	A	MA133	Plot No. S-155 to S-159 & N1, Phase III & Phase IV, Verna Industrial Estate, Verna, Goa, 403 722	India	Blister,Alu/Alu; Blister, Alu-PVC/Aclar	3x1, 3x10, 3x25, 6x1, 6x10, 6x25; 3x1, 3x10, 3x25, 6x1, 6x10, 6x25
	Amodiaquin(as Hydrochloride)+Artesunate (FDC)	270 mg +100 mg	Tablet	Macleods Pharmaceuticals Ltd	A	MA127	Unit 2, Plot No 25-27, Survey No 366, Premier Industrial Estate, Kachigam, Daman, 396 210	India	Blister;Alu/Alu	10x10, 3x1, 3x6, 3x25, 6x25
	Amodiaquin (as Hydrochloride) +(Sulfadoxine+Pyrimethamine)	150mg+ (500mg/25mg)	Co-Blistered tablet	Guilin Pharmaceuticals	A	MA098	Guilin Pharmaceuticals Co. Ltd, No. 43 Quilidian road, Guilin	China	Blister	50x(3+1) 25x(3+1)

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
	Amodiaquine (as Hydrochloride) + Sulfadoxine/ Pyrimethamine	76.5mg+ 250mg/ 12.5mg	Co-blistered Disp tablet	Guilin Pharmaceuticals	A	MA116	Guilin Pharmaceuticals Co. Ltd, No. 43 Quilidian road, Guilin	China	Alu/PVC Blister	50x (3+1)
	Amodiaquine (as Hydrochloride) + Sulfadoxine/ Pyrimethamine	153mg +500mg/ 25mg	Co-blistered Disp tablet	Guilin Pharmaceuticals	A	MA117	Guilin Pharmaceuticals Co. Ltd, No. 43 Quilidian road, Guilin	China	Alu/PVC Blister	50x (3+1)
15	Artesunate + Mefloquine (Co-Blistered)	200 mg + 250 mg	Tablet	Mepha	B	Yes	Dornacherstrasse, Aesch	Switzerland	Co-blister	3+6
16	Artesunate+ Mefloquin (as Hydrochloride) (FDC)	25mg+50mg	Tablet	Cipla Ltd.	A	Yes	Patalganga	India	Alu/Alu strip	1x3, 2x3
17	Artesunate+ Mefloquin (as Hydrochloride) (FDC)	100mg+200mg	Tablet	Cipla Ltd.	A	Yes	Patalganga	India	Alu/Alu strip	1x3, 2x3
	Artesunate + (Sulfadoxine+Pyrimethamine)	50mg+ (500mg+25mg)	Tablet Co-blister	Guilin Pharmaceuticals	A	MA066	Guilin Pharmaceutical Co Ltd, No 43 Qilidian Road, Guilin, Guangxi, 541 004	China	Alu/PVC Co-Blister	1x(3+1), 1x(6+2)
	Artesunate + (Sulfadoxine+Pyrimethamine)	100 mg+ (500mg+25mg)	Tablet Co-blister	Guilin Pharmaceuticals	A	MA068	Guilin Pharmaceutical Co Ltd, No 43 Qilidian Road, Guilin, Guangxi, 541 004	China	Alu/PVC Co-Blister	(3+6) x1, (2+3) x1
21	Chloroquine (as Phosphate)	250mg as phosphate (155mg as base)	Tablet	Alliance Pharmaceuticals, UK	B	Yes	AndersonBrecon (UK) Limited,	UK	HDPE Bottle; Blister	100; 20
	Chloroquine (as Phosphate)	250mg as phosphate (155 mg as base)	Sugar coated Tablet	Remedica	B	Yes	Limassol	Cyprus	PP/PE/ Bottle Al/PVC Blister	500, 1000 10*10 tabs; (100*10 tabs)
22	Mefloquine	250mg	Tablet	Acino	B	Yes	Liesberg	Switzerland	Blister	8
	Mefloquine	250mg	Tablet	Roche, UK	B	Yes	Roche Welwyn Garden City	UK	Blister	8
	Mefloquine	250mg	Tablet	LTT Pharma Lexon UK	B	Yes	Hoffmann-LA Roche	Swiss	Blister	8
	Mefloquine	250mg	Tablet	Mepha Pharma AG, Basel	B	Yes	Acino Pharma AG, Aesch	Switzerland	Blister	4, 6, 8
23	Piperaquine tetraphosphate (as the tetrahydrate; PQP) + Dihydroartemisinin (DHA).	160mg+20mg	Film coated Tablet	Alfasigma S.p.A	A-B	MA093	Pomezia	Italy	PVC/PVdC/Alu blister	3

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
	Dihydroartemisinin/Piperaquine phosphate	20mg +160mg	Disp tablet FDC	Guilin	A	MA141	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	PA/Alu/PVC /Alu	3x1
	Dihydroartemisinin/Piperaquine phosphate	40mg +320mg	Disp tablet FDC	Guilin	A	MA139	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	PA/Alu/PVC /Alu	3x1
	Dihydroartemisinin/Piperaquine phosphate	80mg + 640mg	Tablet FDC	Guilin	A	MA140	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	PA/Alu/PVC /Alu	6x1
	Dihydroartemisinin/Piperaquine phosphate	40mg +320mg	Tablet FDC	Guilin	A	MA131	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	PA/Alu/PVC /Alu	9x1
24	Piperaquine tetraphosphate (as the tetrahydrate; PQP) + Dihydroartemisinin (DHA).	320mg+ 40mg	Film coated Tablet	Alfasigma S.p.A	A-B	MA094	Pomezia	Italy	PVC/PVdC/Alu blister	3, 6 ,9, 12
25	Primaquine	7.5mg (as base) (equivalent to 13.2mg Primaquine Phosphate)	Film coated Tablet	Remedica	B	Yes	Limassol	Cyprus	PP/PE/ Bottle Al/PVC Blister	100; 1000 10*10 tab, 10*100 tab
26	Primaquine	15mg (as base) (equivalent to 26.3mg Primaquine Phosphate)	Tablet	Sanofi / Valeant Pharmaceuticals	B	Yes	Laval, Quebec	Canada	HDPE bottle	100
30	Proguanil	100mg	Tablet	Alliance Pharma (Ireland) Ltd	B	Yes	ANDERSONBRECON (UK) LIMITED WYE VALLEY BUSINESS PARK BRECON ROAD, HAY-ON-WYE, HEREFORD HEREFORDSHIRE, HR3 5PG	UK	HDPE Bottle; Blister	100; 98
27	Quinine Di Hydrochloride	300 mg/ml (600 mg/2 ml or 30 %)	Injectable solution- Route of adminsitration- IV	Renaudin Laboratoire	B	Yes	Zone Artisanale Errobi	France	Ampoule	10, 100

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
28	Quinine Sulphate	300 mg	Film coated Tablet	Remedica	B	Yes	Limassol	Cyprus	P/P Container / Al/PVC Blister	100, 1000 10*10 tabs; 10*100 tabs

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	WHO Prequalification/ SRA	Manufacturing site	Country	Material	Pack
	Quinine Sulphate	300 mg (248mg of quinine base)	Film coated Tablet	Co-Pharma, UK	B	Yes	Strides Arcolab	India	Al/PVC blister packs	2x14tabs, (box of 28 tabs)
	Sulfadoxine+Pyrimethamine	500mg+25mg	Tablet FDC	Guilin Pharmaceuticals	A	MA113	Guilin Pharmaceuticals Co. Ltd, No. 43 Quilidian road,	China	HDPE bottle; Blister	100's,1000's 3', 3x50, 3x100
29	Sulfadoxine + Pyrimethamine	500mg + 25mg	Tablet	Remedica	B	Yes	Limassol	Cyprus	Al/PVC blister PE container	1*3 tabs and , 10* 3tabs 100's and 1000's

End of A or B products list

The Global Fund

List Of Malaria Pharmaceutical Products
classified according to the Global Fund Quality Assurance Policy

Edition: Version 107 - 03rd July 2020

List of ERP (Expert Review Panel) Reviewed Products which are permitted for time limited procurement:

If there is no or only one A or B product available (supply of the product cannot be done within 90 days after the receipt of the Purchase Order by the manufacturer) , grant funds may be used to procure a ERP reviewed product eligible for procurement for limited time (12 months) period. The PR must send the "notification form" (available at https://www.theglobalfund.org/media/5863/psm_notification_form_en.doc) to the Global Fund and upon receiving the " No Objection" letter form the Global Fund, the procurement can proceed. Please note that the QC test of the selected ERP product will be performed by the Global Fund.

Ref.No	International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	Global Fund QA Standard	Period Validity for ERP Review	Manufacturing site	Country	Material	Pack
	Dihydroartemisinin/Piperaquine phosphate	30mg +240mg	Disp tablet FDC	Guilin	ERP reviewed	16-01-21	Oral Solid Dosage Workshop II No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Polyamide(PA)/Aluminium/Polyvinyl Chloride(PVC)/Aluminium blister	3'
	Artemether + Lumefantrine	20mg+120mg	Dispersible tablet	Guilin	ERP reviewed	16-01-21	Oral Solid Dosage Workshop I Guilin Pharmaceutical Co., Ltd No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Alu-PVC/PVdC blister	6'
	Artemether + Lumefantrine	40mg +240mg	Dispersible tablet	Guilin	ERP reviewed	16-01-21	Oral Solid Dosage Workshop I Guilin Pharmaceutical Co., Ltd No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Alu-PVC/PVdC blister	6'
	Artemether + Lumefantrine	60mg +360mg	Dispersible tablet	Guilin	ERP reviewed	16-01-21	Oral Solid Dosage Workshop I Guilin Pharmaceutical Co., Ltd No. 43, Qilidian Road, Guilin 541004, Guangxi	China	Alu-PVC/PVdC blister	6'

	Artesunate	60mg	powder for Injection	Macleods	ERP reviewed	20-03-21	Phase I, Unit II Plot No. 25 – 27, Survey No. 366, Premier Industrial Estate, Kachigam, Daman – 396210 & Immacule Lifesciences Pvt Limited Village Thanthewal, Ropar Road, Nalagarh, Dist.-. Solan Himachal Pradesh - 174101	India	Glas Vial 10 mL	1 vial of artesunate powder is co-packed with Sodium Bicarbonate 50mg/ml injection (solvent) & 5mL Sodium Chloride 9mg/ml injection (diluent).

End of ERP Reviewed products list